Biogen (NASDAQ:BIIB) executives pointed to a “very strong start” to 2026, highlighting growth in key products, progress ...

Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.

Biogen Inc.’s first-quarter sales and profit beat expectations, a sign that the company’s Alzheimer’s drug and cost cuts are ...

The biotech's growth portfolio continues to add to its overall top line.

Biogen (BIIB) stock is in focus as the company beats forecasts with its Q1 2026 financials and trims its full-year earnings ...

Add Yahoo as a preferred source to see more of our stories on Google. The National Institute for Health and Care Excellence (NICE) has recommended natalizumab as an option for adults with highly ...

Biogen has just launched a new app, called Aby, aimed at giving people living with multiple sclerosis (MS) accurate and reliable information about the condition and support. The app is free and gives ...

Biogen Inc. (NASDAQ:BIIB) is one of the best stem cell therapy stocks to buy. On April 22, Biogen Inc. (NASDAQ:BIIB) was ...

Biogen updated the label for its best-selling oral multiple sclerosis drug Tecfidera to include a warning about risk of liver injury that can occur when taking the drug, reports Reuters. The label ...

The European Medicines Agency (EMA) on Friday announced it is provisionally restricting the use of Biogen Idec’s multiple sclerosis (MS) medicine Zinbryta (daclizumab) to patients with highly active ...